PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation

Cholangiocarcinoma (CCA) is a highly malignant tumor with resistance to radiotherapy alone. Olaparib, a highly potent poly(ADP‐ribose) polymerase (PARP) inhibitor, has been shown to sensitize many types of tumor to radiotherapy. However, the effect of olaparib, either as monotherapy or as combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yize, Huang, Xin, Shuang, Zeyu, Lin, Guohe, Wang, Jun, Duan, Fangting, Chen, Jianlin, Li, Shengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911590/
https://www.ncbi.nlm.nih.gov/pubmed/29479816
http://dx.doi.org/10.1002/cam4.1318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911590/
https://www.ncbi.nlm.nih.gov/pubmed/29479816
http://dx.doi.org/10.1002/cam4.1318

Ejemplares similares